This study aims to determine how successful the chemotherapy regimen of Alimta(pemetrexed) plus cisplatin before surgery is at killing all the tumor so that none is left at the time of surgery. Following surgery, all eligible patients will receive radiation to the chest. How patients respond, whether the cancer returns and if so, where, will also be monitored.

Condition	Treatment or Intervention	Phase
Pleural Neoplasms	Drug: Alimta (pemetrexed) and cisplatin	Phase II

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• the tumor can be surgically removed
• no prior treatment, either chemotherapy, surgery, or radiation
• sign informed consent form

Exclusion Criteria:

• prior use of experimental drug
• pregnanacy or breast-feeding
• refusal to have surgery

"There may be multiple sites in this clinical trial".      1-877-CTLILLY (1-877-285-4559 

California
      For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., San Francisco,  California,  United States; Recruiting
Illinois
      For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Chicago,  Illinois,  United States; Recruiting
Maryland
      For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Baltimore,  Maryland,  United States; Recruiting
Massachusetts
      For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Boston,  Massachusetts,  United States; Recruiting
Michigan
      For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Detroit,  Michigan,  United States; Recruiting
New York
      For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., New York,  New York,  United States; Recruiting
Pennsylvania
      For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Philadelphia,  Pennsylvania,  United States; Recruiting
Texas
      For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Houston,  Texas,  United States; Recruiting

Study ID Numbers:  7216
Record last reviewed:  July 2004
Record first received:  July 12, 2004
ClinicalTrials.gov Identifier:  NCT00087698
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-10-29